Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion
NCT ID: NCT01854866
Last Updated: 2013-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
30 participants
INTERVENTIONAL
2013-05-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug-packaging Microparticles
Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
Drug-packaging microparticles
Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug-packaging microparticles
Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huazhong University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bo Huang
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Huang, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Huazhong University of Science and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hubei Provincial Traditional Chinese Medical Hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, Lv M, Li D, Katirai F, Shen GX, Zhang G, Feng ZH, Ye D, Huang B. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun. 2012;3:1282. doi: 10.1038/ncomms2282.
Related Links
Access external resources that provide additional context or updates about the study.
Related information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soundny Biotech
Identifier Type: -
Identifier Source: org_study_id